Enasidenib

Drug Profile

Enasidenib

Alternative Names: AG 221; CC-90007; IDHIFA

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation
  • Class Antineoplastics; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 01 Aug 2017 Registered for Acute myeloid leukaemia (In the elderly, In adults, Late-stage disease, Second-line therapy or greater) in USA (PO) - First global approval
  • 01 Aug 2017 Updated efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Celgene Corporation and Agios Pharmaceuticals
  • 24 Jun 2017 Updated adverse events and efficacy data from phase I/II trial in Haematological malignancies presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top